ulcer
Scope
Date
~
-
Bio & PharmaHK inno.N releases new drug for GERD in Indonesia
South Korean bio-health company HK inno.N Corporation's new drug for gastroesophageal reflux disease (GERD) K-CAB has been officially launched in In...
Jul 10, 2023 (Gmt+09:00)
-
Bio & PharmaHK inno.N's K-CAB to get insurance benefits in China
South Korea’s 30th novel medicine K-CAB Tab (active ingredient: tegoprazan), a gastroesophageal reflux disease (GERD) treatment of HK inno.N, ...
Jan 20, 2023 (Gmt+09:00)
-
Bio & PharmaHK inno.N gets approval to sell K-CAB in Singapore
South Korean biohealth company HK inno.N said on Wednesday that it has received an item approval for K-CAB, a new drug for gastroesophageal reflux d...
Jan 12, 2023 (Gmt+09:00)
-
Bio & PharmaNew drug developer Onconic Therapeutics raises $20 mn in Series B
South Korean drug developer Onconic Therapeutics, announced on Friday that it raised 26 billion won ($19.9 million) in Series B funding, with cumula...
Dec 09, 2022 (Gmt+09:00)
-
Bio & PharmaHK inno.N receives sales permit for ulcer treatment in China
HK inno.N is expediting its global expansion with its latest drug K-Cab designed to treat peptic ulcers.The South Korean pharmaceutical company an...
Apr 13, 2022 (Gmt+09:00)
Latest News
- 1 BMW surpasses Mercedes in Korean sales amid imported vehicle market shake-up
- 2 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 3 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 4 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 5 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
